Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
Overview of attention for article published in Clinical Lymphoma, Myeloma & Leukemia, June 2013
Altmetric Badge
About this Attention Score
-
Good Attention Score compared to outputs of the same age (72nd percentile)
-
Above-average Attention Score compared to outputs of the same age and source (57th percentile)
Readers on
- mendeley
- 90 Mendeley